Arcoma AB logo

ARCOMA - Arcoma AB Share Price

SEK20.1 -0.3  -1.5%

Last Trade - 13/04/21

Micro Cap
Market Cap £22.2m
Enterprise Value £22.9m
Revenue £9.98m
Position in Universe 1350th / 1830
Unlock ARCOMA Revenue
Relative Strength (%)
1m -12.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
123.3 102.1 91.8 119.5 133.7 117.4 158 197 -1.0%
-65.5 +280.7 +59.5
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ArcomaAB revenues decreased 12% to SEK117.4M. Net incomedecreased 78% to SEK1.4M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Net income also reflectsForeign Exchange Gain/Loss–Non-Business decrease fromSEK183K (income) to SEK1.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARCOMA Revenue Unlock ARCOMA Revenue

Net Income

ARCOMA Net Income Unlock ARCOMA Revenue

Normalised EPS

ARCOMA Normalised EPS Unlock ARCOMA Revenue

PE Ratio Range

ARCOMA PE Ratio Range Unlock ARCOMA Revenue

Dividend Yield Range

ARCOMA Dividend Yield Range Unlock ARCOMA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARCOMA EPS Forecasts Unlock ARCOMA Revenue
Profile Summary

Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since November 14, 2014
No. of Shareholders: n/a
No. of Employees: 28
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 12,812,060
Free Float (0.0%)
Eligible for
ARCOMA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARCOMA
Upcoming Events for ARCOMA
Frequently Asked Questions for Arcoma AB
What is the Arcoma AB share price?

As of 13/04/21, shares in Arcoma AB are trading at SEK20.1, giving the company a market capitalisation of £22.2m. This share price information is delayed by 15 minutes.

How has the Arcoma AB share price performed this year?

Shares in Arcoma AB are currently trading at SEK20.1 and the price has moved by 15.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arcoma AB price has moved by -10.07% over the past year.

What are the analyst and broker recommendations for Arcoma AB?

Of the analysts with advisory recommendations for Arcoma AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Arcoma AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Arcoma AB next release its financial results?

Arcoma AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Arcoma AB dividend yield?

Arcoma AB does not currently pay a dividend.

Does Arcoma AB pay a dividend?

Arcoma AB does not currently pay a dividend.

When does Arcoma AB next pay dividends?

Arcoma AB does not currently pay a dividend.

How do I buy Arcoma AB shares?

To buy shares in Arcoma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arcoma AB?

Shares in Arcoma AB are currently trading at SEK20.1, giving the company a market capitalisation of £22.2m.

Where are Arcoma AB shares listed? Where are Arcoma AB shares listed?

Here are the trading details for Arcoma AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: ARCOMA
What kind of share is Arcoma AB?

Based on an overall assessment of its quality, value and momentum, Arcoma AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arcoma AB share price forecast 2021?

Shares in Arcoma AB are currently priced at SEK20.1. At that level they are trading at 22.55% discount to the analyst consensus target price of 0.00.

Analysts covering Arcoma AB currently have a consensus Earnings Per Share (EPS) forecast of 0.79 for the next financial year.

How can I tell whether the Arcoma AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcoma AB. Over the past six months, the relative strength of its shares against the market has been -8.77%. At the current price of SEK20.1, shares in Arcoma AB are trading at -0.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arcoma AB PE Ratio?

The Arcoma AB PE ratio based on its reported earnings over the past 12 months is 98.32. The shares are currently trading at SEK20.1.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Arcoma AB?

Arcoma AB's management team is headed by:

AnnaPia Johansson - CFO
Peter Benson - DRC
Mats Thoren - DRC
Lars Kvarnhem - CHM
Anders Dahlberg - DRC
Katja Kristensson - OTH
Johan Henningsson - VRD
Linda Ungsten - OTH
Nicklas Johansson - COO
Mattias Rundgren - CTR
Frida Robbe - DMK
Alexis Soh - OTH
Who are the major shareholders of Arcoma AB?

Here are the top five shareholders of Arcoma AB based on the size of their shareholding:

Linc AB Corporation
Percentage owned: 27.25% (3.45m shares)
Sunstone Life Science Ventures Fund II K S Individual Investor
Percentage owned: 26% (3.29m shares)
Priego AB Corporation
Percentage owned: 9.09% (1.15m shares)
Bolag (Mats Thoren Med) Individual Investor
Percentage owned: 5.2% (658k shares)
Similar to ARCOMA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.